Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-145 in relapsed or refractory ALL
NCT02028039Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2013
- Primary completion
- Dec 2016
01
Overview
A Phase 2 trial of duvelisib in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Dec 2013; status: withdrawn.
02
Drugs
duvelisib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02028039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028039.